Official Journal of the European Union

C 255/11

Prior notification of a concentration

(Case COMP/M.4402 — UCB/Schwarz Pharma)

(2006/C 255/05)

(Text with EEA relevance)


On 13 October 2006, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking UCB SA (‘UCB’, Belgium) together with its German wholly-owned subsidiary UCB SP Gmbh acquire within the meaning of Article 3(1)(b) of the Council Regulation sole control of the whole of Schwarz Pharma Aktiengesellschaft (‘Schwarz’, Germany), by way of purchase of shares through a public tender offer.


The business activities of the undertakings concerned are:

for UCB: research, development and commercialization of pharmaceuticals and biotechnology products;

for Schwarz: research and development of pharmaceuticals, manufacture and supply of mainly generic medicines.


On preliminary examination, the Commission finds that the notified transaction could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved.


The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax No (32-2) 296 43 01 or 296 72 44) or by post, under reference number COMP/M.4402 — UCB/Schwarz Pharma, to the following address:

European Commission

Directorate-General for Competition

Merger Registry


B-1049 Bruxelles/Brussel

(1)  OJ L 24, 29.1.2004, p. 1.